Bezafibrate

CLINICAL USE

Treatment of metastatic carcinoma of the colon or rectum

DOSE IN NORMAL RENAL FUNCTION

5 mg/kg every 14 days

PHARMACOKINETICS

Molecular weight :149 000

%Protein binding :No data

%Excreted unchanged in urine : No data

Volume of distribution (L/kg) :0.046

half-life – normal/ESRD (hrs) :11–50 days (average 20 days)

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Use with caution

10 to 20 : Use with caution

<10 : Use with caution

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Not dialysed. Use with caution. See ‘Other Information’

HD :Not dialysed. Use with caution. See ‘Other Information’

HDF/high flux :Not dialysed. Use with caution. See ‘Other Information’

CAV/VVHD :Not dialysed. Use with caution. See ‘Other Information’

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugsNone known

ADMINISTRATION

Reconstition

–

Route

IV infusion

Rate of Administration

30–90 minutes depending on how the patient tolerates it

Comments

Dilute in 100 mL of sodium chloride 0.9% DO NOT mix with glucose solutions

OTHER INFORMATION

Increased incidence of hypertension has been seen with treatmentPeople with a history of hypertension may be at an increased risk of proteinuria. Discontinue therapy in patients with Grade 4 proteinuria (nephrotic syndrome)Can delay wound healing Bevacizumab has been used in a haemodialysis patient at a dose of 5 mg/kg every 14 days.

Tags: post-by-auto-php